CDER Head Tidmarsh Faces Lawsuit and Investigation
George Tidmarsh, head of the FDA's Center for Drug Evaluation and Research (CDER), has been placed on administrative leave amid an investigation into his personal conduct.
A lawsuit claims Tidmarsh abused his position to harm a former business associate, Kevin Tang, and Aurinia Pharma, a company in which Tang is an investor.
Tidmarsh believed the probe into his conduct was prompted by concerns he raised about a new fast-track programme for the rapid approval of some drugs.
- Tidmarsh was named CDER director in July.
- The investigation is ongoing, with Tidmarsh on leave.
Author's summary: CDER head Tidmarsh sued and on leave amid investigation.